Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Rarity PBC Closes $4.6M Seed Round to Advance Gene Therapy for ADA-SCID
SeedVenture Capital

Rarity PBC Closes $4.6M Seed Round to Advance Gene Therapy for ADA-SCID

•October 29, 2025
•Oct 29, 2025
0

Participants

Rarity

Rarity

company

Nemean Capital

Nemean Capital

investor

Why It Matters

The funding backs a potentially curative therapy for a life‑threatening rare disease, accelerating its path to market and underscoring investor confidence in biotech ventures structured as public benefit corporations.

Deal Summary

Rarity PBC announced the closing of a $4.6M seed financing led by biotech investor Steve Oliveira of Nemean Asset Management to accelerate development of its autologous hematopoietic stem cell gene therapy for ADA-SCID.

0

Comments

Want to join the conversation?

Loading comments...